Stocks in play: Manulife Financial Corp.
Over the last five years, has seen a sharp spike in the number of adults submitting claims for ADHD medications, and newly released data suggests that this trend shows no signs of slowing. According to Manulife's latest Special Report on Employee Health Insights, from 2021 to 2022 the number of unique claimants for ADHD medication, ages 18 and over, grew by 24.5%. This is compared to an average claimant growth rate of 15.3% from 2017 – 2021. Manulife Financial Corp. T.MFC shares T.MFC are trading unchanged at $25.55.
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.